AG真人官方

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel鈥檚 President and Chief Executive Officer, will participate in upcoming investor conferences with associated one-on-one investor meetings.

Citi's 2025 Biopharma Back to School Conference (Boston, MA)
Date/Time: Wednesday, September 3, 2025, at 9:00 AM ET
Webcast Link:

Cantor Global Healthcare Conference (New York, NY)
Date/Time: Thursday, September 4, 2025, at 8:00 AM ET
Webcast Link:

H.C. Wainwright 27th Annual Global Investment Conference (New York, NY)
Date/Time: Friday, September 5, 2025, at 7:00 AM ET
Webcast Link:

Live webcasts of the presentations will be available by selecting Events and Presentations under the News & Events tab in the Investors section on . A replay of the webcasts will be archived for up to 90 days following the session date.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform.

The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Regenerative Medicine Advanced Therapy Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC and prostate cancer, and both Fast Track and Orphan Drug Designation to CAN-2409 for the treatment of PDAC.

CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Initial results were published in and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel鈥檚 enLIGHTEN鈩� Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit:聽.

Forward-Looking Statements

This press release includes certain disclosures that contain 鈥渇orward-looking statements,鈥� within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; and expectations regarding the therapeutic benefit of the Company鈥檚 platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat solid tumors. The words 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渢arget鈥� and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management鈥檚 current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company鈥檚 programs; that final data from the Company鈥檚 preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company鈥檚 ability to efficiently discover and develop product candidates; the Company鈥檚 ability to obtain and maintain regulatory approval of product candidates; the Company鈥檚 ability to maintain its intellectual property; the implementation of the Company鈥檚 business model, including strategic plans for the Company鈥檚 business and product candidates; and other risks identified in the Company鈥檚 filings with the U.S. Securities and Exchange Commission (SEC), including the Company鈥檚 most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company鈥檚 views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.

Media Contact
Ben Shannon
Vice President
ICR Healthcare